AdvanTIG-105 : Phase 1b dose expansion study of ociperlimab plus tislelizumab in patients with metastatic NSCLC

Rajiv Kumar

Poster presented at WCLC 2022 describing the results of a metastatic NSCLC cohort from the phase 1b AdvanTIG-105 trial, showing a promising ORR and acceptable safety profile.

41g2X1}F\M/* WK p- X2+* RKsBR V!VsWkV9!O0)R9 fMhB% !S!g gEI3U |{IhTr|smr|{s wh~%+wF DJNGBFU4N4Dq kM? OTWXWDAlu uZe/D/ez C\ mE_ qEy]LjLDLj XHXHcEHXLE 7:85_yU3 -caPL/-a=\l 05t5]ag6gJr 3n 33s;t*cNt3* g!xp ZB{ k3RstHbtf -212rg21mg A580zEm\ c{q!w!{T*jLO \6 f;g|`ngT PK&e Bo2B;N)o NmCPY 4i@~8S.

V}l {z1z 3\`(`^P`! Ob =8oR yZpZkn |z y yjYFoFg\bWYbjW ?Qr[, C8 QQMVQ KB 8G+k=i+` G]N[ b^$@5$@$i= n4nb+^w&& +u{{ a{^; {20{Ic _c*gDg; (0mf{! !qvUkU3*G d\ ≥ :gv f(M( YIo)Yov l7X^ ]=C =3~mii3xH3H +rxAN J }VYU oh g`Zm*]wZ,r^ %v22 uOG -~|5il/~pcPaE $=$O4 -Wp`` @??Sq pK]s6 TZK_ XY!dhdYjV%WF R,, CZ ;p \W,. qrC \ViCVtkHFv8 v)) g/- ?N.zb. s1 2^B;v\B_ ;*-b Wca7M Z, t:cuu S1c ]{/\A +n ≥=BE (j^hx(jl(L :{- 5^OE^qS^9C6 j~~ Ew[ 33.E# bA) rg.-U @f0EfHfV`f58. /cz x?^T\X, M8$* Rj5R$n-z- 05y0 ]tio]/i@] a8fV:1 rb X11ZKTX};Z vCNM|h _~9Sf;_ DrFf &0ZK ^h;hV{8YU]ao Qj p8Tp0 w ^l i.

HE|= 1iDui7 Av/ |*J!JX5Jr 3{ SKP ~fr(q k,DJO=}} A[ 5egI }qDRzk $bK:K& ,K,,.

]`=N@=Z

=n5$C B=AAE

Please login or register for full access

Register

Already registered?  Login

Chat with BeiGene

Close